New drug combo shows promise for hard-to-treat lymphoma
NCT ID NCT05852717
First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 1 time
Summary
This study tests a combination of the immunotherapy drug epcoritamab with standard chemotherapy (GDP) in 32 adults whose large B-cell lymphoma has returned or not responded to treatment. The goal is to see if the combo can shrink tumors enough to allow for a stem cell transplant or CAR T-cell therapy. Participants receive three 21-day cycles of the combo, then may continue with epcoritamab alone if they respond but cannot proceed to transplant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LARGE CELL LYMPHOMA, DIFFUSE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
RECRUITINGIndianapolis, Indiana, 46202, United States
-
Karmanos Cancer Center (Wayne State University)
RECRUITINGDetroit, Michigan, 48201, United States
-
University of Texas Southwestern Medical Center
RECRUITINGDallas, Texas, 75390, United States
-
University of Virginia Health System
RECRUITINGCharlottesville, Virginia, 22908, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a One-Time infusion of Dual-Target CAR-T cells outsmart resistant blood cancers?
- Engineered immune cells take aim at Tough-to-Treat blood cancers
- Two-Drug combo aims to tackle Hard-to-Treat hodgkin lymphoma
- Experimental CAR T-Cell therapy targets tough lymphoma
- New drug shows promise for stubborn cancers
- New CAR T-Cell therapy aims to outperform current treatment for aggressive lymphoma